🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the effort against drug-resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting over 82 million instances annually. Particularly high rates are observed in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the reality of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Public health authorities are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance showed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers hope that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This approval signifies a significant shift in the management of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

According to data released by a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which involves a dual-drug approach. The research enrolled nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to license and sell the drug in many developing nations.

Doctors on the front lines have expressed positive views. Having a one-pill regimen such as this is hailed as a "game-changer" for gonorrhoea control. This is viewed as vital to lessen the impact of the disease for individuals and to halt the transmission of extremely resistant gonorrhoea worldwide.